Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

Matthew J. Matasar, Stefano Luminari, Paul M. Barr, Stefan K. Barta, Alexey V. Danilov, Brian T. Hill, Tycel J. Phillips, Mats Jerkeman, Massimo Magagnoli, Loretta J. Nastoupil, Daniel O. Persky, Jessica Okosun

Research output: Contribution to journalArticle

Abstract

Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. Presently, there is no consensus for treatment of patients with early or multiply relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. Although the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This review considers prognostication and the evolving treatment landscape of FL, including recent and emergent therapies as well as remaining unmet needs. Implications for Practice: In follicular lymphoma, a personalized approach to management based on disease biology, patient characteristics, and other factors continues to emerge. However, application of current management requires an understanding of the available therapeutic options for first-line treatment and knowledge of current development in therapies for previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies.

Original languageEnglish
JournalOncologist
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Follicular Lymphoma
Therapeutics
Tumor Burden

Keywords

  • Antineoplastic agents
  • Follicular lymphoma
  • Neoplasms
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Matasar, M. J., Luminari, S., Barr, P. M., Barta, S. K., Danilov, A. V., Hill, B. T., ... Okosun, J. (2019). Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. Oncologist. https://doi.org/10.1634/theoncologist.2019-0138

Follicular Lymphoma : Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. / Matasar, Matthew J.; Luminari, Stefano; Barr, Paul M.; Barta, Stefan K.; Danilov, Alexey V.; Hill, Brian T.; Phillips, Tycel J.; Jerkeman, Mats; Magagnoli, Massimo; Nastoupil, Loretta J.; Persky, Daniel O.; Okosun, Jessica.

In: Oncologist, 01.01.2019.

Research output: Contribution to journalArticle

Matasar, MJ, Luminari, S, Barr, PM, Barta, SK, Danilov, AV, Hill, BT, Phillips, TJ, Jerkeman, M, Magagnoli, M, Nastoupil, LJ, Persky, DO & Okosun, J 2019, 'Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs', Oncologist. https://doi.org/10.1634/theoncologist.2019-0138
Matasar, Matthew J. ; Luminari, Stefano ; Barr, Paul M. ; Barta, Stefan K. ; Danilov, Alexey V. ; Hill, Brian T. ; Phillips, Tycel J. ; Jerkeman, Mats ; Magagnoli, Massimo ; Nastoupil, Loretta J. ; Persky, Daniel O. ; Okosun, Jessica. / Follicular Lymphoma : Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. In: Oncologist. 2019.
@article{6da98004571c4a4c98901fd773eff336,
title = "Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs",
abstract = "Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. Presently, there is no consensus for treatment of patients with early or multiply relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. Although the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This review considers prognostication and the evolving treatment landscape of FL, including recent and emergent therapies as well as remaining unmet needs. Implications for Practice: In follicular lymphoma, a personalized approach to management based on disease biology, patient characteristics, and other factors continues to emerge. However, application of current management requires an understanding of the available therapeutic options for first-line treatment and knowledge of current development in therapies for previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies.",
keywords = "Antineoplastic agents, Follicular lymphoma, Neoplasms, Non-Hodgkin lymphoma",
author = "Matasar, {Matthew J.} and Stefano Luminari and Barr, {Paul M.} and Barta, {Stefan K.} and Danilov, {Alexey V.} and Hill, {Brian T.} and Phillips, {Tycel J.} and Mats Jerkeman and Massimo Magagnoli and Nastoupil, {Loretta J.} and Persky, {Daniel O.} and Jessica Okosun",
year = "2019",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2019-0138",
language = "English",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",

}

TY - JOUR

T1 - Follicular Lymphoma

T2 - Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

AU - Matasar, Matthew J.

AU - Luminari, Stefano

AU - Barr, Paul M.

AU - Barta, Stefan K.

AU - Danilov, Alexey V.

AU - Hill, Brian T.

AU - Phillips, Tycel J.

AU - Jerkeman, Mats

AU - Magagnoli, Massimo

AU - Nastoupil, Loretta J.

AU - Persky, Daniel O.

AU - Okosun, Jessica

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. Presently, there is no consensus for treatment of patients with early or multiply relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. Although the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This review considers prognostication and the evolving treatment landscape of FL, including recent and emergent therapies as well as remaining unmet needs. Implications for Practice: In follicular lymphoma, a personalized approach to management based on disease biology, patient characteristics, and other factors continues to emerge. However, application of current management requires an understanding of the available therapeutic options for first-line treatment and knowledge of current development in therapies for previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies.

AB - Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. Presently, there is no consensus for treatment of patients with early or multiply relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. Although the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This review considers prognostication and the evolving treatment landscape of FL, including recent and emergent therapies as well as remaining unmet needs. Implications for Practice: In follicular lymphoma, a personalized approach to management based on disease biology, patient characteristics, and other factors continues to emerge. However, application of current management requires an understanding of the available therapeutic options for first-line treatment and knowledge of current development in therapies for previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies.

KW - Antineoplastic agents

KW - Follicular lymphoma

KW - Neoplasms

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85070288652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070288652&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2019-0138

DO - 10.1634/theoncologist.2019-0138

M3 - Article

AN - SCOPUS:85070288652

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -